Determination of Tolrestat, a Novel Aldose Reductase Inhibitor, in Serum and Tissues
- 1 September 1984
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 6 (3) , 328-333
- https://doi.org/10.1097/00007691-198409000-00013
Abstract
An UV spectrophotometric method and a high-performance liquid chromatographic (HPLC) method were developed for the determination of tolrestat, a novel aldose reductase inhibitor, in serum. The limits of detection of the methods are 15 and 0.2 .mu.g/ml, respectively. With human serum, a modification of the HPLC method provides sensitivity to 25 ng/ml. The specificity of the methods were compared. The HPLC method can be applied to the lens and the sciatic nerve. [Tolrestat can effectively reduce the accumulation of dulcitol in the lens and sciatic nerve of galactosemic rats, and can also reduce tissue levels of sorbitol in streptozotocin diabetic rats.].This publication has 1 reference indexed in Scilit:
- Synthesis of [14C]‐labelled tolrestat(N‐[[5‐(trifluoromethyl)‐6‐methoxy‐1‐naphthalenyl]‐[14C]thioxomethyl]‐N‐methylglycine; AY‐27, 773)Journal of Labelled Compounds and Radiopharmaceuticals, 1984